Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chinese Academy of Sciences STING compound 5c: sourced facts only. name: "Extensive structure-activity relationship (SAR) study allowed us to identify compound 5c with cellular human- and mouse-STING inhibitory IC50 values of 44 and 32 nM, respectively." [PMID:40614559]; target: "Extensive structure-activity relationship (SAR) study allowed us to identify compound 5c with cellular human- and mouse-STING inhibitory IC50 values of 44 and 32 nM, respectively." [PMID:40614559]; developer: "Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China; Lingang Laboratory, Shanghai, 200031, PR China; ShanghaiTech University, School of Physical Science & Technology, Shanghai, 201210, PR China." [PMID:40614559]; stage: "Compound 5c also demonstrated robust in vivo anti-inflammatory efficacy on STING agonist-stimulated systemic inflammation and cisplatin-induced acute kidney injury (AKI) mice models." [PMID:40614559]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chinese Academy of Sciences STING compound 5c.